GlassScriptPhysician profile
Wael Yacoub
NPI 1770546533
$18,116.97
in general payments reported to CMS, 2019-2025
44 companies · $2,846 in 2025
The $2,846 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,745 · 2020: $1,933 · 2021: $2,162 · 2022: $2,441 · 2023: $2,419 · 2024: $2,571 · 2025: $2,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,614 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,614.13 |
| Education | $221.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,505.76 | 2019-2025 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $2,909.65 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $2,727.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,288.43 | 2020-2025 | Linzess, Viberzi, Ubrelvy |
| Lilly USA, LLC | $882.12 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $617.43 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $515.94 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $503.25 | 2021-2025 | |
| Allergan, INC. | $455.04 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $432.70 | 2019-2025 | Xifaxan, Relistor, Cycloset |
| Pfizer INC. | $413.02 | 2019-2024 | |
| Astellas Pharma US INC | $392.21 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $357.81 | 2019-2022 | |
| Exact Sciences Corporation | $321.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $302.09 | 2020-2025 | Nexletol |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Yacoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.